Medicenna Therapeutics Corp. MDNA
0.16 +0.16
Day range unavailable
52-week range unavailable
- Earnings date
- Nov 3, 2023
No chart data for this range yet.
Key statistics
- Price / sales
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Nov 3, 2023
Expected Nov 3, 2023. Consensus EPS estimate 0.00.
Financials — quick view
MDNA Revenue — quarterly 0
MDNA Net income — quarterly -2.86M
MDNA EPS — quarterly -0.04
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2023 | Sep 1, 2023 | -0.05 | — | — | — |
| Jul 28, 2023 | Jun 1, 2023 | -0.04 | — | — | — |
| Jun 27, 2023 | Mar 1, 2023 | -0.06 | — | — | — |
| Feb 7, 2023 | Dec 1, 2022 | -0.06 | — | — | — |
| Nov 4, 2022 | Sep 1, 2022 | -0.06 | — | — | — |
| Aug 15, 2022 | Jun 1, 2022 | -0.07 | — | — | — |
News
Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease 
Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting 
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms 
Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026 
Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs 
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet 
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities 
Medicenna Announces the Launch of a Marketed Public Offering of Securities 
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma 
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
Your note
Sign in to keep a note on MDNA — it syncs with the Stock Master app.